


- Efficacies in rat models (ED50, mg/kg)

Compound	Carrageenan-Induced Edema	Carrageenan-Induced Hyperalgesia	Adjuvant Arthritis (AA)
AAT-076	2.7	4.0	0.08
Celebrex™	7	35	0.3

- Cortical Renal Blood Flow in Anesthetized Volume-Depleted Rats




Data are expressed as Mean + SEM.

*: p<0.05 compared to Vehicle or Furosemide group by t-test.

X = fold the estimated anti-inflammatory exposure at the ED₅₀ in the rat AA model.

- Mean Pain Relief (0-24 hr), Categorical (Range 0-4), LOCF



#: Statistically significant differences (p<0.05) were observed vs. Ibuprofen with Fisher's Protected LSD Comparisons.

Statistically significant differences vs. Placebo were observed after 30 min to 24 hr post dosing at 180 and 360 mg treatment groups, after 45 min to 24 hr post dosing at 60 mg treatment group.

- The mechanism of action is proven in the market.
- Safety differentiation suggested based on preclinical studies.
- Chemical structure is very different from known coxibs, e.g. celecoxib.
- Fast onset and long duration of pain relief compared to ibuprofen is confirmed in a post-operative dental pain study.